Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 1 for:    NCT01508247
Previous Study | Return to List | Next Study

A Clinical Trial to Assess the Efficacy and Safety of an Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Aged 6-35 Months

This study has been completed.
Sponsor:
Collaborator:
Bejing Vigoo Biological Co., LTD
Information provided by (Responsible Party):
Jiangsu Province Centers for Disease Control and Prevention
ClinicalTrials.gov Identifier:
NCT01508247
First received: January 4, 2012
Last updated: March 27, 2013
Last verified: March 2013

January 4, 2012
March 27, 2013
January 2012
March 2013   (final data collection date for primary outcome measure)
the incidence density of the EV71-associated diseases in the vaccine group and placebo group. [ Time Frame: begin at day 56 up to 14 months ] [ Designated as safety issue: No ]
compare the incidence density of the EV71-associated diseases between the vaccine group and placebo group in Chinese children aged 6-35 months.
Same as current
Complete list of historical versions of study NCT01508247 on ClinicalTrials.gov Archive Site
  • the frequency of all the adverse events in vaccine group and placebo group. [ Time Frame: up to 14 months ] [ Designated as safety issue: Yes ]
    compare frequency of all the solicited events, unsolicited adverse events and serious adverse events between vaccine group and placebo group.
  • Seropositive rate of the vaccine group [ Time Frame: 8 months after first vaccination ] [ Designated as safety issue: No ]
    calculate the seropositive rate of the vaccine group in Chinese children aged 6-35 months at month 8 after first vaccination.
  • Seroconversion rate of the vaccine group [ Time Frame: 8 months after first vaccination ] [ Designated as safety issue: No ]
    calculate the seroconversion rate of the vaccine group in Chinese children aged 6-35 months at month 8 after first vaccination.
  • GMT of the vaccine group [ Time Frame: 8 months after first vaccination ] [ Designated as safety issue: No ]
    calculate the geometric mean titre (GMT) of the vaccine group in Chinese children aged 6-35 months at month 8 after first vaccination.
  • Seropositive rate of the vaccine group [ Time Frame: 14 months after first vaccination ] [ Designated as safety issue: No ]
    calculate the seropositive rate of the vaccine group in Chinese children aged 6-35 months at month 14 after first vaccination.
  • Seroconversion rate of the vaccine group [ Time Frame: 14 months after first vaccination ] [ Designated as safety issue: No ]
    calculate the seroconversion rate of the vaccine group in Chinese children aged 6-35 months at month 14 after first vaccination.
  • GMT of the vaccine group [ Time Frame: 14 months after first vaccination ] [ Designated as safety issue: No ]
    calculate the geometric mean titre (GMT) of the vaccine group in Chinese children aged 6-35 months at month 14 after first vaccination.
  • Seropositive rate of the vaccine group and placebo group [ Time Frame: 28 days after the second vaccination ] [ Designated as safety issue: No ]
    compare the seropositive rate of the vaccine group and placebo group in healthy children aged 6-35 months.
  • Seroconversion rate of the vaccine group and placebo group [ Time Frame: 28 days after the second vaccination ] [ Designated as safety issue: No ]
    compare the Seroconversion rate of the vaccine group and placebo group in healthy children aged 6-35 months.
  • GMT of the vaccine group and placebo group [ Time Frame: 28 days after the second vaccination ] [ Designated as safety issue: No ]
    compare the geometric mean titre (GMT) of the vaccine group and placebo group in healthy children aged 6-35 months.
  • GMI of the vaccine group and placebo group [ Time Frame: 28 days after the second vaccination ] [ Designated as safety issue: No ]
    compare the geometric mean fold increase (GMFI) of the vaccine group and placebo group in healthy children aged 6-35 months.
  • the frequency of all the adverse events in vaccine group and placebo group. [ Time Frame: up to 14 months ] [ Designated as safety issue: Yes ]
    compare frequency of all the solicited events, unsolicited adverse events and serious adverse events between vaccine group and placebo group.
  • Seropositive rate of the vaccine group [ Time Frame: 8 months after first vaccination ] [ Designated as safety issue: No ]
    caculate the seropositive rate of the vaccine group in Chinese children aged 6-35 months at month 8 after first vaccination.
  • Seroconversion rate of the vaccine group [ Time Frame: 8 months after first vaccination ] [ Designated as safety issue: No ]
    caculate the seroconversion rate of the vaccine group in Chinese children aged 6-35 months at month 8 after first vaccination.
  • GMT of the vaccine group [ Time Frame: 8 months after first vaccination ] [ Designated as safety issue: No ]
    caculate the GMT of the vaccine group in Chinese children aged 6-35 months at month 8 after first vaccination.
  • Seropositive rate of the vaccine group [ Time Frame: 14 months after first vaccination ] [ Designated as safety issue: No ]
    caculate the seropositive rate of the vaccine group in Chinese children aged 6-35 months at month 14 after first vaccination.
  • Seroconversion rate of the vaccine group [ Time Frame: 14 months after first vaccination ] [ Designated as safety issue: No ]
    caculate the seroconversion rate of the vaccine group in Chinese children aged 6-35 months at month 14 after first vaccination.
  • GMT of the vaccine group [ Time Frame: 14 months after first vaccination ] [ Designated as safety issue: No ]
    caculate the GMT of the vaccine group in Chinese children aged 6-35 months at month 14 after first vaccination.
  • Seropositive rate of the vaccine group and placebo group [ Time Frame: 28 days after the second vaccination ] [ Designated as safety issue: No ]
    compare the seropositive rate of the vaccine group and placebo group in healthy children aged 6-35 months.
  • Seroconversion rate of the vaccine group and placebo group [ Time Frame: 28 days after the second vaccination ] [ Designated as safety issue: No ]
    compare the Seroconversion rate of the vaccine group and placebo group in healthy children aged 6-35 months.
  • GMT of the vaccine group and placebo group [ Time Frame: 28 days after the second vaccination ] [ Designated as safety issue: No ]
    compare the GMT of the vaccine group and placebo group in healthy children aged 6-35 months.
  • GMI of the vaccine group and placebo group [ Time Frame: 28 days after the second vaccination ] [ Designated as safety issue: No ]
    compare the GMI of the vaccine group and placebo group in healthy children aged 6-35 months.
Not Provided
Not Provided
 
A Clinical Trial to Assess the Efficacy and Safety of an Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Aged 6-35 Months
A Multiple-center Randomized Double-blind Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of an Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Aged 6-35 Months

Since its discovery in 1969, enterovirus 71 (EV71) has been recognised as a frequent cause of epidemics of hand-foot-mouth disease (HFMD) associated with severe neurological sequelae in a small proportion of cases. There has been a significant increase in EV71 epidemic activity throughout the Asia-Pacific region since 1997. Recent HFMD epidemics in this region have heen associated with a severe from of brainstem encephalitis associated with pulmonary oedema and high case-fatality rates.

The data from the phase 1 and 2 trials suggested that the inactivated EV71 vaccine had a clinically acceptable safety and good immunogenicity for healthy Chinese children and infants. According to the immunogenicity and safety results, the 320U with adjuvant with immunizing schedule of two doses (per 28 day) will be applied in phase 3 clinical trial.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
  • Hand, Foot and Mouth Disease
  • Herpangina
  • Other EV71-associated Diseases
  • Biological: inactivated vaccine (Vero Cell) against EV71
    inactivated vaccine (vero cell) against EV71, 320U /0.5ml, two doses, on day0, 28
  • Biological: 0/0.5ml placebo
    0/0.5ml placebo, two doses, on day0, 28
  • Experimental: vaccine against EV71
    Inactivated vaccine (Vero Cell) against EV71 of 320U /0.5ml in 5000 children aged 6-35 months on day0, 28
    Intervention: Biological: inactivated vaccine (Vero Cell) against EV71
  • Placebo Comparator: placebo
    0/0.5ml placebo in 5000 children aged 6-35 months on day0, 28
    Intervention: Biological: 0/0.5ml placebo
Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang YT, Yao X, Chu K, Chen QH, Hu YM, Wu X, Liu P, Zhu LY, Gao F, Jin H, Chen YJ, Dong YY, Liang YC, Shi NM, Ge HM, Liu L, Chen SG, Ai X, Zhang ZY, Ji YG, Luo FJ, Chen XQ, Zhang Y, Zhu LW, Liang ZL, Shen XL. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013 May 28. doi:pii: S0140-6736(13)61049-1. 10.1016/S0140-6736(13)61049-1. [Epub ahead of print]

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10245
March 2013
March 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

Only subjects fulfilling all of the following criteria will be eligible for the study:

  • Healthy children aged from 6 to 35 months old
  • General good health as established by medical history and physical examination
  • The subjects' guardians are able to understand and sign the informed consent
  • Had never received the vaccine against EV71
  • The subjects' guardians allow to comply with the requirements of the protocol
  • Available for all visits scheduled in this study
  • Subjects with temperature <=37.0°C on axillary setting

Exclusion Criteria:

Subjects will not be eligible for the study if any of the following criteria is met:

  • Subject who has a medical history of HFMD
  • Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine
  • Family history of seizures or progressive neurological disease
  • Family history of congenital or hereditary immunodeficiency
  • Severe malnutrition or hypogenesis
  • Major congenital defects or serious chronic illness, including perinatal brain damage
  • Autoimmune disease
  • Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with IM injections or blood draws
  • Asplenia, functional asplenia, or splenic excision
  • History of asthma, angioneurotic edema, diabetes or malignant tumour
  • History of thyroidectomy, or thyroid disease in last 12 months
  • Any acute infections in last 7 days
  • Any prior administration of immunodepressant or corticosteroids in last 6 months
  • Any prior administration of blood products in last 3 months
  • Any prior administration of other research vaccines or medicines in last 1 month
  • Any prior administration of attenuated live vaccine in last 15 days
  • Any prior administration of subunit or inactivated vaccines in last 7 days
  • Under the anti-TB prevention or therapy
  • Subjects with temperature >37.0°C on axillary setting
  • Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives

Exclusion Criteria for the second dose:

Subjects will not be eligible for the second dose if any of following adverse events happened after the first dose. They can continue other process of the study without the second dose vaccination according to the opinion of the investigator.

  • Had any serious adverse events related to the first dose of inactivated vaccine (vero cell) against EV71 within 7 days
  • Hypersensitivity reactions after vaccination (including urticaria/rashes that occur within 30 minutes after inoculation)
  • Anaphylaxis after vaccination
  • Any confirmed or suspected autoimmune disease or immune deficiency diseases, including human immunodeficiency virus (HIV) infection
  • Any condition that in the opinion of the investigator, or IRB
Both
6 Months to 35 Months
No
Contact information is only displayed when the study is recruiting subjects
China
 
NCT01508247
JSVCT010
Yes
Jiangsu Province Centers for Disease Control and Prevention
Jiangsu Province Centers for Disease Control and Prevention
Bejing Vigoo Biological Co., LTD
Principal Investigator: Feng-Cai Zhu, Master Jiangsu Provincial Center for Diseases Control and Prevention
Jiangsu Province Centers for Disease Control and Prevention
March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP